"To evaluate the use of the Dexcom CGM System when used according to approved commercial labeling during standard clinical use and its impact on intended users in a real-world setting"
Enrollment is complete. The trial is in its follow-up or data collection phase — a readout may occur on or near the primary completion date.
DexCom Inc (DXCM) is the sponsoring company for this trial. BiotechSign currently grades this company F (17/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.